Stocks · News reference

Molecular Partners Reports H1 2026 Financial Results With Net Loss Narrowing To CHF 26.7M From CHF 37.2M YoY, And Cash Position Of CHF 67.9M

Aug 25, 2026, 5:22 AMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 25, 2026, 10:15 AMBenzinga Newsdesk
Molecular Partners Q2 EPS $(0.89) Misses $(0.45) Estimate
Molecular Partners (NASDAQ:MOLN) reported quarterly losses of $(0.89) per share which missed the analyst consensus estimate of $(0.45) by 95.56 percent. This is a 31.34 percent decrease over losses of $(0.67) per share
MOLN
BenzingaJul 16, 2026, 5:47 AMBenzinga Newsdesk
Molecular Partners Reports Nine Active Trial Sites And Ongoing Treatment In Phase 2 MP0317 Cholangiocarcinoma Study, With Data Update Expected In 2027 And Completion In 2028
Randomized Phase 2 study in front-line setting progressing well, with nine sites actively recruiting and patient treatment ongoingData update expected in 2027, with trial completion in 2028Trial-in-progress poster to be
MOLN
BenzingaJul 15, 2026, 5:34 AMBenzinga Newsdesk
Molecular Partners Highlights Multispecific Radio-DARPins Formatted As Bispecific Or 2-In-1 DuoDARPin To Address Tumor Heterogeneity
Developing bispecific Radio-DARPins to engage multiple tumor targets simultaneously, improving precision and therapeutic efficacyPresentation outlines Radio-DARPins’ ability to match target and disease biology for
MOLN